Elsevier

Journal of Hepatology

Volume 68, Issue 2, February 2018, Pages 335-352
Journal of Hepatology

Review
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

https://doi.org/10.1016/j.jhep.2017.09.021Get rights and content

Summary

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common forms of chronic liver disease worldwide and its prevalence is expected to continue rising. NAFLD has traditionally been considered a consequence of metabolic syndrome (MetS). However, the link between NAFLD and MetS components, especially type 2 diabetes mellitus (T2DM), hypertension (HTN), and cardiovascular disease (CVD) is more complex than previously thought. Indeed, the adverse effects of NAFLD extend far beyond the liver, with a large body of clinical evidence now suggesting that NAFLD may precede and/or promote the development of T2DM, HTN and atherosclerosis/CVD. The risk of developing these cardiometabolic diseases parallels the underlying severity of NAFLD. Accumulating evidence suggests that the presence and severity of NAFLD is associated with an increased risk of incident T2DM and HTN. Moreover, long-term prospective studies indicate that the presence and severity of NAFLD independently predicts fatal and nonfatal CVD events. In this review, we critically discuss the rapidly expanding body of clinical evidence that supports the existence of a bi-directional relationship between NAFLD and various components of MetS, particularly T2DM and HTN, as well as the current knowledge regarding a strong association between NAFLD and CVD morbidity and mortality. Finally, we discuss the most updated putative biological mechanisms through which NAFLD may contribute to the development of HTN, T2DM and CVD.

Introduction

Non-alcoholic fatty liver disease (NAFLD) defines the hepatic consequences of over-nutrition in individuals without secondary causes of hepatic steatosis, and encompasses a spectrum of pathologic conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), with or without cirrhosis and hepatocellular carcinoma (HCC).[1], [2]

NAFLD represents a major public health problem.3 The prevalence of the disease is increasing in parallel with the pandemic of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS), and is as high as 25% in the general adult population in Western countries.4 NAFLD is also significantly associated with increased long-term morbidity and mortality, primarily owing to cardiovascular disease (CVD).[1], [5], [6]

Several epidemiological studies suggested that NAFLD may be both a consequence and a cause of metabolic syndrome and its individual features, and that the link of NAFLD/NASH with type 2 diabetes, hypertension and cardiovascular disease is more complex than previously believed.

Traditionally considered as the simple “hepatic manifestation” of MetS, owing to its strong association with abdominal obesity, atherogenic dyslipidaemia, T2DM and hypertension (HTN), NAFLD has even closer mutual interrelationships with T2DM and other MetS components than previously thought.[2], [7], [8], [9] Indeed, on the one hand, MetS and its individual components predict the development and progression of NAFLD;[10], [11], [12], [13], [14] on the other hand, NAFLD is a precursor for the future development of MetS components.[6], [9], [15], [16], [17], [18], [19], [20], [21], [22], [23] Accordingly, it has also been suggested that ultrasonographic changes in NAFLD status over time may affect the risk of incident T2DM, HTN and other MetS components.[24], [25], [26]

Collectively, these findings have fuelled a “chicken and egg” dilemma regarding the temporal and causal relationship between NAFLD and cardiometabolic risk: is NAFLD a consequence or a cause of MetS and its individual components? Some recent community-based studies have developed this research question further by suggesting the existence of a bi-directional relationship and reciprocal causality relating NAFLD to T2DM and MetS.[22], [27], [28], [29], [30]

Herein, we critically discuss the rapidly expanding body of clinical evidence that supports the existence of a bi-directional relationship between NAFLD and MetS components (especially T2DM and HTN), whilst also reviewing current knowledge surrounding the strong link between NAFLD and increased risk of incident CVD. Special attention will be paid to prospective studies that used imaging methods or biopsies to diagnose NAFLD. Finally, we also briefly discuss the putative pathophysiological mechanisms linking NAFLD to the risk of incident HTN, T2DM and CVD.

Section snippets

NAFLD and hypertension

Blood pressure has a continuous and consistent relationship with the risk of incident CVD. As such, HTN, affecting around 30% of the general population, is one of the strongest risk factors for CVD.[31], [32]

Up to 50% of hypertensive patients have NAFLD and several studies reported a strong association between blood pressure and NAFLD in both hypertensive and normotensive individuals.[33], [34], [35] Presence and severity of NAFLD have also been associated with increased arterial stiffness and

Diabetes increases risk of NAFLD

Patients with established T2DM display a high prevalence of NAFLD. Indeed, in these patients, NAFLD ranges from approximately 45% to 75% in large hospital-based studies and from 30% to 70% in population-based studies.57 For example, in the Valpolicella Heart Diabetes Study, involving nearly 3,000 Italian outpatients with T2DM, the prevalence of NAFLD on ultrasonography was 69.5%.58

Substantial evidence also indicates that people with T2DM are at high risk of developing NASH, and a twofold to

NAFLD and cardiovascular disease

NAFLD typically exists in a “milieu” of altered metabolism, including central obesity, dysglycaemia, atherogenic dyslipidaemia and HTN. Cumulatively, these aetiological factors increase the risk of CVD, so it is rational that CVD is the leading cause of death in patients with NAFLD.

Several authors have investigated the possible association between NAFLD and the risk of prevalent and incident CVD.[59], [83], [84], [85], [86] Whilst the association between NAFLD and increased CVD prevalence seems

Arterial hypertension

HTN has been associated with increased fibrosis progression in NAFLD.[126], [127] Experimentally, it has been shown that the renin-angiotensin-aldosterone (RAA) system may influence the development of HTN and hepatic fibrosis in rat models,128 as well as the occurrence of albuminuria in human NAFLD.51 Moreover, specific genetic polymorphisms encoding angiotensinogen are more common in patients with NASH than in control subjects,129 and a specific single nucleotide polymorphism of angiotensin II

Conclusions

This review reinforces the notion that NAFLD is a multisystem disease, which plays an important role in the development of atherosclerosis/CVD, T2DM and other cardiometabolic diseases by disrupting the regulation of multiple metabolic and inflammatory pathways.

Strong evidence indicates that the global health burden of NAFLD is not only confined to progressive liver disease, but also embraces major extra-hepatic complications. Indeed, the leading causes of mortality among patients with NAFLD are

Financial support

GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy.

Conflict of interest

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contributions

Study concept and design: AL, FN, AM, GT; acquisition of data: AL, FN, AM, GT; analysis and interpretation of data: AL, FN, AM, GT; drafting of the manuscript: AL, FN, AM, GT.

References (216)

  • G. Targher et al.

    Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?

    J Hepatol

    (2011)
  • N. Li et al.

    Non-alcoholic fatty liver disease is associated with progression of arterial stiffness

    Nutr Metab Cardiovasc Dis

    (2015)
  • S. McPherson et al.

    Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

    J Hepatol

    (2015)
  • S.H. Wild et al.

    Type 2 diabetes and risk of hospital admission or death for chronic liver diseases

    J Hepatol

    (2016)
  • G. Baffy et al.

    Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

    J Hepatol

    (2012)
  • G. Targher et al.

    Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes

    J Hepatol

    (2010)
  • G. Targher et al.

    Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?

    Diabetes Metab

    (2016)
  • K. Bjorkstrom et al.

    Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease

    Clin Gastroenterol Hepatol

    (2017)
  • A. Lonardo et al.

    Non-alcoholic fatty liver disease and risk of cardiovascular disease

    Metab Clin Exp

    (2016)
  • A.L. Fracanzani et al.

    Carotid artery intima-media thickness in nonalcoholic fatty liver disease

    Am J Med

    (2008)
  • L.A. Adams et al.

    The natural history of nonalcoholic fatty liver disease: a population-based cohort study

    Gastroenterology

    (2005)
  • EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

    J Hepatol

    (2016)
  • AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

    Dig Liver Dis

    (2017)
  • Z.M. Younossi et al.

    The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

    Hepatology

    (2016)
  • Z.M. Younossi et al.

    Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

    Hepatology

    (2016)
  • M. Ekstedt et al.

    Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

    Hepatology

    (2015)
  • P. Wainwright et al.

    Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome

    Int J Mol Sci

    (2016)
  • M. Hamaguchi et al.

    The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

    Ann Intern Med

    (2005)
  • A. Tsuneto et al.

    Fatty liver incidence and predictive variables

    Hypertens Res

    (2010)
  • P. Sorrentino et al.

    Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension

    Am J Gastroenterol

    (2010)
  • S. Singh et al.

    Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

    Clin Gastroenterol Hepatol

    (2015)
  • L.A. Adams et al.

    NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study

    Am J Gastroenterol

    (2009)
  • K. Lau et al.

    The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study

    J Hypertens

    (2010)
  • K.C. Sung et al.

    Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes

    Diabetes Care

    (2012)
  • S.K. Park et al.

    Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study

    Hepatology

    (2013)
  • J.H. Ryoo et al.

    Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension

    J Korean Med Sci

    (2014)
  • J.H. Ryoo et al.

    Clinical association between non-alcoholic fatty liver disease and the development of hypertension

    J Gastroenterol Hepatol

    (2014)
  • S. Ballestri et al.

    Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis

    J Gastroenterol Hepatol

    (2016)
  • Y. Hashimoto et al.

    Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals

    Endocrine

    (2017)
  • K.C. Sung et al.

    Resolution of fatty liver and risk of incident diabetes

    J Clin Endocrinol Metab

    (2013)
  • H. Yamazaki et al.

    Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes

    Diabetes Care

    (2015)
  • Y. Zhang et al.

    Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population

    BMJ Open

    (2015)
  • S. Ballestri et al.

    The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment

    Hepatol Res

    (2016)
  • Y. Li et al.

    Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study

    PLoS One

    (2017)
  • G. Mancia et al.

    2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

    Eur Heart J

    (2013)
  • A. Lopez-Suarez et al.

    Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase

    Eur J Gastroenterol Hepatol

    (2011)
  • L.Y. Qian et al.

    Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population: Normal is not the new normal

    Medicine

    (2016)
  • R. Lorbeer et al.

    Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease

    J Hypertens

    (2017)
  • M.T. Long et al.

    Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study

    Arterioscler Thromb Vasc Biol

    (2015)
  • E.C. Aneni et al.

    Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk

    J Hypertens

    (2015)
  • Cited by (0)

    View full text